[1] |
Zhu HB,Li B,Li CZ,et al. The clinical features,recurrence risks and surgical strategies of bone invasive pituitary adenomas[J]. Clin Neurol Neurosurg,2021,201: 106455. doi: 10.1016/j.clineuro.2020.106455
|
[2] |
Li CZ,Zhu HB,Zong XY,et al. Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China:surgical results in a cohort of 2032 patients,operated between 2006 and 2018[J]. Clin Neurol Neurosurg,2020,197: 106176. doi: 10.1016/j.clineuro.2020.106176
|
[3] |
Raverot G,Burman P,McCormack A,et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol,2018,178(1): G1-G24. doi: 10.1530/EJE-17-0796
|
[4] |
Kobyakov GL,Chernov IV,Astafieva LI,et al. Use of chemotherapy in the treatment of aggresive pituitary adenomas[J]. Zh Vopr Neirokhir Im N N Burdenko,2020,84(1): 69-75. doi: 10.17116/neiro20208401169
|
[5] |
Marques JVO,Boguszewski CL. Fertility issues in aggressive pituitary tumors[J]. Rev Endocr Metab Disord,2020,21(2): 225-233. doi: 10.1007/s11154-019-09530-y
|
[6] |
Liu XS,Tang C,Wen GD,et al. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas[J]. Front Endocrinol (Lausanne),2018,9: 768.
|
[7] |
Rudman Y,Duskin-Bitan H,Manisterski Y,et al. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma:does size really matter?[J]. Clin Endocrinol (Oxf),2021,95(4): 606-617. doi: 10.1111/cen.14541
|
[8] |
Tang H,Cheng YJ,Huang JY,et al. Case report:temozolomide treatment of refractory prolactinoma resistant to dopamine agonists[J]. Front Endocrinol (Lausanne),2021,12: 616339. doi: 10.3389/fendo.2021.616339
|
[9] |
Lasolle H,Ilie MD,Raverot G. Aggressive prolactinomas:how to manage?[J]. Pituitary,2020,23(1): 70-77. doi: 10.1007/s11102-019-01000-7
|
[10] |
Araujo-Castro M,Pian H,Ruz-Caracuel I,et al. Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas[J]. Endocr Connect,2021,10(1): 102-109. doi: 10.1530/EC-20-0414
|
[11] |
Shimatsu A,Nakamura A,Takahashi Y,et al. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma:a multicenter,single-arm,phase 3 study in Japan[J]. Endocr J,2021,68(7): 791-805. doi: 10.1507/endocrj.EJ20-0707
|
[12] |
Tokutsu A,Okada Y,Torimoto K,et al. Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases[J]. Neuro Endocrinol Lett,2020,41(1): 10-16.
|
[13] |
Polat Korkmaz O,Gurcan M,Nuhoglu Kantarci FE,et al. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly[J]. Pituitary,2019,22(4): 387-396. doi: 10.1007/s11102-019-00968-6
|
[14] |
Yamamoto M,Nakao T,Ogawa W,et al. Aggressive cushing’s disease:molecular pathology and its therapeutic approach[J]. Front Endocrinol (Lausanne),2021,12: 650791. doi: 10.3389/fendo.2021.650791
|
[15] |
Dai CX,Fan YH,Liu XH,et al. Predictors of immediate remission after surgery in cushing’s disease patients:a large retrospective study from a single center[J]. Neuroendocrinology,2021,111(11): 1141-1150. doi: 10.1159/000509221
|
[16] |
Zhuang Z,Liu XH,Bao XJ,et al. Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection:a case report and literature review[J]. Medicine (Baltimore),2018,97(46): e13148.
|
[17] |
Barbot M,Mondin A,Regazzo D,et al. Incretin response to mixed meal challenge in active cushing’s disease and after pasireotide therapy[J]. Int J Mol Sci,2022,23(9): 5217. doi: 10.3390/ijms23095217
|
[18] |
Gadelha M,Bex M,Feelders RA,et al. Randomized trial of osilodrostat for the treatment of cushing disease[J]. J Clin Endocrinol Metab,2022,107(7): e2882-e2895. doi: 10.1210/clinem/dgac178
|
[19] |
Witek P,Mehlich A,Stasiewicz A,et al. Osilodrostat - an emerging drug for the medical management of Cushing’s disease[J]. Endokrynol Pol,2022,73(2): 371-374. doi: 10.5603/EP.a2022.0009
|
[20] |
Fleseriu M,Newell-Price J,Pivonello R,et al. Long-term outcomes of osilodrostat in Cushing’s disease:LINC 3 study extension[J]. Eur J Endocrinol,2022,187(4): 531-541. doi: 10.1530/EJE-22-0317
|
[21] |
Cohen AC,Goldney DC,Danilowicz K,et al. Long-term outcome after bilateral adrenalectomy in Cushing’s disease with focus on Nelson’s syndrome[J]. Arch Endocrinol Metab,2019,63(5): 470-477.
|
[22] |
Beck-Peccoz P,Giavoli C,Lania A. A 2019 update on TSH-secreting pituitary adenomas[J]. J Endocrinol Invest,2019,42(12): 1401-1406. doi: 10.1007/s40618-019-01066-x
|
[23] |
Yoon JH,Choi W,Park JY,et al. A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer;a case report and literature review[J]. BMC Endocr Disord,2021,21(1): 177. doi: 10.1186/s12902-021-00839-x
|
[24] |
Dai CX, Liu XH, Ma SH, et al. Management of refractory/aggressive pituitary adenomas review of current treatment options[M]//Da Silva Junior EB, Milano JB. Primary Intracranial Tumors. Rijeka: IntechOpen, 2019: 858.
|
[25] |
McCormack A,Dekkers OM,Petersenn S,et al. Treatment of aggressive pituitary tumours and carcinomas:results of a European Society of Endocrinology (ESE) survey 2016[J]. Eur J Endocrinol,2018,178(3): 265-276. doi: 10.1530/EJE-17-0933
|
[26] |
Park HH,Kim EH,Ku CR,et al. Outcomes of aggressive surgical resection in growth hormone-secreting pituitary adenomas with cavernous sinus invasion[J]. World Neurosurg,2018,117: e280-e289. doi: 10.1016/j.wneu.2018.06.012
|
[27] |
Albano L,Losa M,Barzaghi LR,et al. Gamma knife radiosurgery for pituitary tumors:a systematic review and meta-analysis[J]. Cancers (Basel),2021,13(19): 4998. doi: 10.3390/cancers13194998
|
[28] |
Wang ZX,Tang ZY,Zhao HL,et al. Treatment of recurrent undifferentiated pleomorphic sarcoma of infratemporal Fossa by surgery combined with carbon ion radiotherapy:one case report[J]. Front Surg,2021,8: 693774. doi: 10.3389/fsurg.2021.693774
|
[29] |
Woznick WK,Engel A,Maas D. A rare case of metastatic transformation to pituitary carcinoma[J]. J. Endocr. Soc.,2021,5(Supplement_1): A565-A566.
|
[30] |
Minniti G,Paolini S,Rea MLJ,et al. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas[J]. J Neurooncol,2020,149(1): 123-130. doi: 10.1007/s11060-020-03579-5
|
[31] |
Luo M,Tan YH,Chen WL,et al. Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas:a systematic review and meta-analysis[J]. Front Neurol,2021,12: 700007. doi: 10.3389/fneur.2021.700007
|
[32] |
Elbelt U,Schlaffer SM,Buchfelder M,et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a German survey[J]. J Clin Endocrinol Metab,2020,105(3): dgz211. doi: 10.1210/clinem/dgz311
|
[33] |
Ishida A,Shichi H,Fukuoka H,et al. Temozolomide and capecitabine treatment for an aggressive somatotroph pituitary tumor:a case report and literature review[J]. Front Oncol,2022,12: 916982. doi: 10.3389/fonc.2022.916982
|
[34] |
Das L,Gupta N,Dutta P,et al. Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas[J]. Front Endocrinol (Lausanne),2021,12: 774686. doi: 10.3389/fendo.2021.774686
|
[35] |
Gao HL,Wang WQ,Yu XJ,et al. Patterns and predictors of pancreatic neuroendocrine tumor prognosis:are no two leaves alike?[J]. Crit Rev Oncol Hematol,2021,167: 103493. doi: 10.1016/j.critrevonc.2021.103493
|
[36] |
Sorbye H,Kong G,Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)[J]. Endocr Relat Cancer,2020,27(3): R67-R77. doi: 10.1530/ERC-19-0400
|
[37] |
Giuffrida G,Ferraù F,Laudicella R,et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors:a monocentric experience[J]. Endocr Connect,2019,8(5): 528-535. doi: 10.1530/EC-19-0065
|
[38] |
Assadi M,Nemati R,Shooli H,et al. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy[J]. Eur J Nucl Med Mol Imaging,2020,47(4): 1015-1016. doi: 10.1007/s00259-019-04578-z
|
[39] |
Osterhage K,Rotermund R,Droste M,et al. Bevacizumab in aggressive pituitary adenomas - experience with 3 patients[J]. and,2021,129(3): 178-185.
|
[40] |
Wang Y,He QW,Meng XJ,et al. Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma:case report and literature review[J]. World Neurosurg,2019,S1878-S8750(19): 30044-0.
|
[41] |
Zhang DY,Way JS,Zhang XH,et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas[J]. J Clin Endocrinol Metab,2019,104(6): 1929-1936. doi: 10.1210/jc.2018-02461
|
[42] |
Cooper O,Bonert VS,Rudnick J,et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas[J]. J Clin Endocrinol Metab,2021,106(2): e917-e925. doi: 10.1210/clinem/dgaa805
|
[43] |
Gnanalingham K, Zador Z, Kearney T, et al. Pituitary tumours[M]//Kirollos R, Helmy A, Thomson S, et al. Oxford Textbook of Neurological Surgery. Oxford: Oxford University Press, 2019: 299-320.
|
[44] |
Duhamel C,Ilie MD,Salle H,et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas:two case reports and a review of the literature[J]. J Pers Med,2020,10(3): 88. doi: 10.3390/jpm10030088
|
[45] |
Caccese M,Barbot M,Ceccato F,et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab[J]. Anticancer Drugs,2020,31(2): 199-204. doi: 10.1097/CAD.0000000000000856
|